Eli Lilly To Introduce Obesity Drug in India Next year: Eli Lilly CEO

Photo:Representative Image

Eli Lilly anticipates to introduce its obesity drug tirzepatide in India as soon as the following year, David Ricks, the U.S. drugmaker's President added.

"We're open to any way to reach more patients as long as it makes sense for the company and we can supply the market," Ricks mentioned when asked if Lilly was open to allowing authorised generic versions of tirzepatide.

The medication is sold under the name Mounjaro for diabetes and Zepbound for weight reduction in the US. India ought to help patent security, dispose of excess strategies and make a social wellbeing net to win huge funds from worldwide drugmakers, Ricks said in his feature address at the BioAsia meeting in the southern Indian province of Telangana.

Lilly and Danish opponent Novo Nordisk make profoundly compelling and famous medications for diabetes and weight reduction, which have a place with a class of medicines known as GLP-1 agonists. Last year, a top Novo Nordisk official told that it is focusing to bring its blockbuster weight reduction drug Wegovy in India in 2026.

The worldwide market for these medicines is supposed to reach somewhere around $100 billion before the decade's over, as per investigator gauges. 

Eli Lilly and Company is an American drug firm settled in Indianapolis, Indiana, with workplaces in 18 nations. Its items are sold in roughly 125 nations. The organization was established in 1876 by, and named after, Colonel Eli Lilly, a drug scientist and an Association Armed force veteran of the American Nationwide conflict.